CY1117275T1 - METHODS OF THERAPEUTIC TREATMENT WITH THE USE OF ENANTI-ERBB-MEFANTSINOID ANTIBODY conjugates - Google Patents

METHODS OF THERAPEUTIC TREATMENT WITH THE USE OF ENANTI-ERBB-MEFANTSINOID ANTIBODY conjugates

Info

Publication number
CY1117275T1
CY1117275T1 CY20151100433T CY151100433T CY1117275T1 CY 1117275 T1 CY1117275 T1 CY 1117275T1 CY 20151100433 T CY20151100433 T CY 20151100433T CY 151100433 T CY151100433 T CY 151100433T CY 1117275 T1 CY1117275 T1 CY 1117275T1
Authority
CY
Cyprus
Prior art keywords
erbb
methods
antibody conjugates
mefantsinoid
enanti
Prior art date
Application number
CY20151100433T
Other languages
Greek (el)
Inventor
Sharon Erickson
Ralph Schwall
Mark X Sliwkowski
Walter Dr Blattler
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP10010047.8A external-priority patent/EP2283866B1/en
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of CY1117275T1 publication Critical patent/CY1117275T1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η αίτηση αφορά μεθόδους θεραπευτικής αγωγής με τη χρήση συζευγμάτων αντισώματος έναντι- ErbB-μεϊτανσινοειδούς και ειδών παραγωγής καταλλήλων για χρήση σε τέτοιες μεθόδους. Συγκεκριμένα, η εφεύρεση αφορά θεραπείες καρκίνου οι οποίες κατευθύνονται στον υποδοχέα ErbB με τη χρήση συζευγμάτων αντισώματος έναντι- ErbB-μεϊτανσινοειδούς.The application relates to methods of treatment using ErbB-methanthinoid antibody conjugates and species suitable for use in such methods. In particular, the invention relates to cancer therapies directed to the ErbB receptor using anti-ErbB-methanthinoid antibody conjugates.

CY20151100433T 1999-06-25 2015-05-14 METHODS OF THERAPEUTIC TREATMENT WITH THE USE OF ENANTI-ERBB-MEFANTSINOID ANTIBODY conjugates CY1117275T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14131699A 1999-06-25 1999-06-25
US18984400A 2000-03-16 2000-03-16
EP10010047.8A EP2283866B1 (en) 1999-06-25 2000-06-23 Methods of treatment using anti-erbb antibody-maytansinoid conjugates

Publications (1)

Publication Number Publication Date
CY1117275T1 true CY1117275T1 (en) 2017-04-26

Family

ID=58461631

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20141100652T CY1115480T1 (en) 1999-06-25 2014-08-13 METHODS OF THERAPEUTIC TREATMENT WITH THE USE OF ENANTI-ERBB-MEFANTSINOID ANTIBODY conjugates
CY20151100433T CY1117275T1 (en) 1999-06-25 2015-05-14 METHODS OF THERAPEUTIC TREATMENT WITH THE USE OF ENANTI-ERBB-MEFANTSINOID ANTIBODY conjugates

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20141100652T CY1115480T1 (en) 1999-06-25 2014-08-13 METHODS OF THERAPEUTIC TREATMENT WITH THE USE OF ENANTI-ERBB-MEFANTSINOID ANTIBODY conjugates

Country Status (1)

Country Link
CY (2) CY1115480T1 (en)

Also Published As

Publication number Publication date
CY1115480T1 (en) 2017-01-04

Similar Documents

Publication Publication Date Title
CY1120070T1 (en) METHOD OF THERAPEUTIC TREATMENT WITH THE USE OF ANTI-ERBB-METHYSINEOID ANTIBODY conjugates
CY1119291T1 (en) LITTLE ANTIBODIES AND USES FOR THEM
CY1109525T1 (en) HUMANIZED ANTI-ErbB2 ANTIBODIES AND THERAPEUTIC TREATMENT WITH ANTI-ErbB2 ANTIBODIES
CY1112458T1 (en) A PARTICULAR SPECIAL FOR BAFF SOLUTION FOR USE IN CANCER
CY1107628T1 (en) HUMAN CTLA-4 ANTIBODIES AND USES
CY1112862T1 (en) UNIQUE ANTIQUES SHRAPS USEFUL AS THERAPEUTIC
CY1117387T1 (en) Monoclonal N-11 Dispersed β-Amyloid Antibodies, COMPOSITIONS, METHODS AND USES
CY1108074T1 (en) IMMUNOLOGICAL METHODS FOR REGULATING MYOSTATIN IN SCIENCE
DK1187632T3 (en) Treatment with anti-ErbB2 antibodies
CY1115730T1 (en) THERAPEUTIC SITES AND THEIR USES
CY1112055T1 (en) COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF LUNG TUMOR
CY1113243T1 (en) METHODS OF TREATMENT USING CTLA-4
CY1105078T1 (en) COMPETITORS TECH
CY1113489T1 (en) ANTIBODY THAT INCLUDES ALPHABETA7 INTEGRINE AND USE THIS IN THE THERAPEUTIC TREATMENT OF THE INFLAMMATORY INTELLIGENCE
CY1113984T1 (en) DM1 conjugate conjugate products with TRASTUZUMAB antibody, CONNECTED THROUGH NON-EXTRACTIVE CONNECTOR AND USE IN TREATMENT TREATMENT
DK1572087T3 (en) Antibodies with cancer antigen TMEFF2 and applications thereof
CY1109817T1 (en) OLIGO-BETA (1,3) -GLUCAN AND MONOCLONIC ANTIBODIES AGAINST CANCER
ATE442861T1 (en) PHOTODYNAMIC THERAPY DIRECTED AGAINST ANTIBODIES
CY1105380T1 (en) PREFERRED NEURAL FILAMENT PROTEIN PORTIONS AND METHODS OF USING THEREOF
DE60113445D1 (en) SUBSTANCES WITH BRANCHED LINKERMOLEKÜLEN
CY1106200T1 (en) ANTIBODIES TO CASPASE-8, THEIR PREPARATION AND USE
CY1117275T1 (en) METHODS OF THERAPEUTIC TREATMENT WITH THE USE OF ENANTI-ERBB-MEFANTSINOID ANTIBODY conjugates
DE69915690D1 (en) ANTI-CONVULSIVE DERIVATIVES FOR TREATING POST-TRAUMATIC STRESS DISEASES
CY1106363T1 (en) USE OF ACTIVATED COAGULATION FACTOR VII IN THE MANAGEMENT OF MAJOR BLEEDING INDUCED BY THROMBOLITIC THERAPY
UY26170A1 (en) ANTIGEN (C42) ASSOCIATED WITH TUMORS